SeaPRwire
Read More

The Humanoids Launches 3D Art and 4K Renders, Becoming One of the Few Projects To Do So

pandora
4 minutes

New York, USA / December 15, 2021 / SEAPRWire / – The Humanoids [Humanoids], a blockchain-based company offering a set of unique NFTs, have announced the launch of its 3D art and 4K renders. The first of a few projects to release 4K renders in the non-fungible token market, The Humanoids has released a set of 10,000 unique Humanoids that live on the Ethereum blockchain. A utility-offering project, The Humanoids offers holders of Humanoids NFTs exclusive access to benefits ranging from giveaways to raffle draws, airdrops, etc. Furthermore, the 3D art has been made as relatable as possible. Rendered in 4K, The Humanoids ensure that minute details [shadows, lightings, accessories] about these art pieces are seen unquestionably. Each of the Humanoids has been generated from a mix of over 150 distinct traits. While all are dope, The Humanoids ensure that some are rarer than others. Oftentimes, first-time investors overlook rarities when picking Humanoids, they simply go for those that reflect their personality. Another remarkable facet of The Humanoids is its tight-knitted community. Owners of Humanoids get to enjoy unique benefits as well become members of a community driven by sheer l...

ACN Newswire
Read More

Metalist Lab Receives AP License to Publish NFT Collections of 53 UNIQUE Moments from the Past 100 Years on BinanceNFT

indie
3 minutes

New York, NY, Oct 9, 2021 - (ACN Newswire via SEAPRWire.com) - Recently, Metalist Lab has announced a partnership with the Associated Press. And it is authorized by AP to release unique moments collection in the near future. For 175 years, the Associated Press has provided the world with accurate and fast news reporting of the most important events around the globe. With fearless staff and news bureaus in 250 locations in 100 countries, AP journalists have covered moments of great joy, scientific breakthroughs, achievement, and accomplishment as well as moments of loss, despair and agony.AP is dropping a unique, curated collection of its rare, archived news reporting of the most memorable moments in recent world history. To release this unique series of collectibles, AP is collaborating with Metalist Lab and the collection will drop on the Binance NFT marketplace on October 19th, at 12pm UTC.Related link on Twitter: https://twitter.com/AssociatedPressThe collectibles feature AP's coverage over the past 100 years of milestones in space, global conflicts, science and discovery, and human freedoms and advancement. The news reporting at the core of this collection consists of high-reso...

ACN Newswire
Read More

Mandalika Circuit could emerge as favorite in racing world: Expert

indie
3 minutes

Lombok Island, Indonesia, Jul 28, 2021 - (ACN Newswire via SEAPRWire.com) - The Mandalika Circuit in Lombok, West Nusa Tenggara, which is expected to be completed by 2022, has the potential to become a new favorite in the international racing world, an expert has said. "Once it is finished, this circuit will be gorgeous, and the track is flowing. This fast circuit will be the new favorite in the international racing world," motorsport aficionado Arief Kurniawan told ANTARA last Thursday (July 22, 2021).Mandalika Circuit has a unique selling point: It is in the Special Economic Zone (KEK Mandalika), surrounded by beautiful beaches and the Indian Ocean.Dorna Sports S.L. has designated Mandalika Circuit as one of the venues for MotoGP.Mandalika's developer, the Indonesian Tourism Development Corporation (ITDC), is targeting completion of the 4.3-km circuit with 17 corners to meet the specifications and pass the homologation test of the International Motorcycling Federation (FIM).The Mandalika Grand Prix Association, the circuit's promoter and operator, noted that as of mid-July this year, construction work on the circuit was 81.42 percent complete. Meanwhile, work on the run-off grave...

ACN Newswire
Read More

Maculus Therapeutix welcomes Privity, Prepares Capital Raise for Novel Drug Delivery Platform

indie
3 minutes

SANTA CLARA, CA & DUBAI, Feb 19, 2021 - (ACN Newswire) - Maculus Therapeutix, a preclinical-stage biopharmaceutical company that has developed a SINGLE injection platform to treat wet AMD (Age-related Macular Degeneration) and DME (Diabetic Macular Edema) instead of the standard 8-12 monthly injections, is pleased to welcome Privity FZ LLE as a partner and advisor for upcoming fundraising activities. Maculus plans to raise $3 million at an $8 million valuation for a 12-18 month period, including initial in-vivo animal studies and completion of in-vitro / in-vivo drug elution studies.Maculus achieved the breakthrough using a patented novel tunable biodegradable proprietary product, called MacuBloc. Capable of delivering any FDA approved drug for wet AMD / DME to the site of the disease, with unique suitability for targeted and extended delivery of drugs to the back of the human eyes, MacuBloc offers significant benefits to Wet AMD patients such as a single intravitreal injection that lasts a year rather than the current monthly injections, and a potential reduction in inflammation, infection, doctor visits and total cost of care.Syed H Askari, PhD, Founder, Chief Executive Offic...

ACN Newswire
Read More

Maculus Therapeutix welcomes Privity FZ LLE and Prepares Capital Raise for Novel Drug Delivery Platform

indie
4 minutes

SANTA CLARA, CA & DUBAI, Feb 17, 2021 - (ACN Newswire) - Maculus Therapeutix, a preclinical-stage biopharmaceutical company which has developed a SINGLE injection delivery platform for diseases such as wet AMD (Age-related Macular Degeneration) and DME (Diabetic Macular Edema) instead of the standard 8-12 monthly injections, is pleased to welcome Privity FZ LLE as a partner and advisor for upcoming fundraising activities. Maculus plans to raise USD3 million with a USD8 million valuation for a 12-18 month period, including initial in-vivo animal studies and completion of in-vitro / in-vivo drug elution studies.Maculus achieved the breakthrough using a patented novel tunable biodegradable proprietary product, MacuBloc, capable of delivering any FDA approved drugs for Wet AMD / DME to the site of the disease, with unique suitability for targeted and extended delivery of drugs to the back of the human eyes, MacuBloc offers significant benefits to Wet AMD patients: a single intravitreal injection that lasts a year rather than the current monthly injections, and a potential reduction in inflammation, infection, doctor visits and total cost of care, compared to current practice.Syed H...